Montag A & Associates Inc Moon Lake Immunotherapeutics Transaction History
Montag A & Associates Inc
- $2.14 Billion
- Q3 2025
A detailed history of Montag A & Associates Inc transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Montag A & Associates Inc holds 7 shares of MLTX stock, worth $89. This represents 0.0% of its overall portfolio holdings.
Number of Shares
7Holding current value
$89% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding MLTX
# of Institutions
181Shares Held
38.5MCall Options Held
4.13MPut Options Held
1.54M-
Bvf Inc San Francisco, CA19.8MShares$252 Million7.66% of portfolio
-
Avoro Capital Advisors LLC New York, NY2MShares$25.5 Million0.2% of portfolio
-
Cormorant Asset Management, LP Boston, MA1.99MShares$25.5 Million2.28% of portfolio
-
Balyasny Asset Management LLC Chicago, IL1.7MShares$21.7 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.5MShares$19.2 Million0.02% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $472M
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...